Vaccine genetics of IGHV1-2 VRC01-class broadly neutralizing antibody precursor naïve human B cells.
Jeong Hyun LeeLaura ToyJustin T KosYana SafonovaWilliam R SchiefColin Havenar-DaughtonCorey T WatsonShane CrottyPublished in: NPJ vaccines (2021)
A successful HIV vaccine eliciting broadly neutralizing antibodies (bnAbs) must overcome the hurdle of being able to activate naive precursor B cells encoding features within their germline B cell receptors (BCR) that allow recognition of broadly neutralizing epitopes. Knowledge of whether bnAb precursor B cells are circulating at sufficient frequencies within individuals in communities heavily impacted by HIV may be important. Using a germline-targeting eOD-GT8 immunogen and high-throughput droplet-based single-cell BCR sequencing, we demonstrate that large numbers of paired BCR sequences from multiple donors can be efficiently screened to elucidate precursor frequencies of rare, naive VRC01-class B cells. Further, we analyzed IGHV1-2 allelic usage among three different cohorts; we find that IGHV1-2 alleles traditionally thought to be incompatible with VRC01-class responses are relatively common in various human populations and that germline variation within IGHV1-2 associates with gene usage frequencies in the naive BCR repertoire.
Keyphrases
- hiv infected
- single cell
- acute lymphoblastic leukemia
- high throughput
- antiretroviral therapy
- tyrosine kinase
- chronic myeloid leukemia
- endothelial cells
- human immunodeficiency virus
- hiv positive
- rna seq
- dna repair
- dengue virus
- hepatitis c virus
- hiv testing
- hiv aids
- induced pluripotent stem cells
- healthcare
- pluripotent stem cells
- men who have sex with men
- genome wide
- zika virus
- cancer therapy
- south africa
- copy number
- gene expression
- dna methylation
- genetic diversity